Details of the Drug-Related molecule(s) Interaction Atlas
General Information of Drug (ID: DMYXOU2)
Drug Name | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
AGN-190205; AGN-191659; AGN-191701; AGN-192326; AGN-192327; AGN-192509; AGN-192599; AGN-192870; AGN-194277; AGN-195393; AGN-4202; ALRT-326; ALRT-4204; LGD-4204; LGD-4326; NRX-194202; RXR ligands, ALRT; RXR ligands, Allergan; Retinoid X receptor agonists, ALRT; Retinoid X receptor agonists, Allergan; VTP-4204; RXR agonists, Allergan/Pfizer; Rexinoid receptor agonist (cancer), NuRx; RXR agonists (cancer/ diabetes), Vitae Pharmaceuticals; RXR agonists, Allergan/Parke-Davis
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecule-Related Drug Atlas
Molecule-Related Drug Atlas
Molecule Type:
DTT Drug Status:
Approved Drug(s) Clinical Trial Drug(s) Discontinued Drug(s) Investigative Drug(s) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug(s) Targeting Retinoic acid receptor RXR-gamma (RXRG)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Molecular Interaction Atlas | |||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
References